@thenasheffect
1/ New in @JTO_IASLC: Our ONWARD SCLC consortium reports real-world tarlatamab outcomes in SCLC! There were 265 patients across 11 US centers. The median number of prior lines was 2, 44.5% had brain metastases, and 39.2% had liver metastases.View quoted post on X
jto.org/article/S1556-…
ascopubs.org Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk | JCO... PurposeTo characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement.MethodsWe... 📣EPCAM study that was a simultaneous @CGAIGC abstract presentation & publication in @JCOPO_ASCO: Pts w/full gene EPCAM deletions that don’t extend into MSH2 don’t have Lynch syndrome. People tested <2013 may need repeat testing to clarify diagnosis. @AmbryGenetics @TempusAIView quoted post on X
Voting for ASCO Election is open! I am so honored to run among other great candidates for ASCO nominating committee. We are all very excited to serve ASCO mission, vision & broader community! Visit asco.org/election to learn more about all candidates and cast your vote!View quoted post on X
